Company expects to complete Phase 2 MOMENTUM trial enrollment in Q1 2027
Initial Phase 2 MOMENTUM trial data expected in 2H 2027
Company expects current cash to fund operations to end of 2028
Result drivers
Roche collaboration - Q2 revenue growth was primarily driven by revenue recognized under the new Roche DAC collaboration agreement
Lower personnel costs - Decrease in R&D and G&A expenses was mainly due to reduced personnel costs from lower stock-based compensation
Analyst coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 7 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for C4 Therapeutics, Inc. is $11.00, about 203.9% above its August 10 closing price of $3.62
Quarterly results beat estimates
US biopharma firm's Q2 revenue rose slightly, beating analyst expectations
Q2 net loss per share was $0.18, better than analyst estimates
CCCC•
